The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Plus: A startup bioengineering off-the-shelf arteries, how viruses may cause Alzheimer’s, water-powered satellites and more.

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

The study reveals a potential link between concussions and the activation of dormant viruses, which may lead to ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

New research suggests that concussions and repetitive head trauma may reactivate dormant viruses like HSV-1 in the brain, potentially triggering neurodegenerative diseases such as Alzheimer’s.

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

Discover the surprising link between herpes and Alzheimer's disease. Find out how the common herpes simplex virus may play a ...

Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Global Central Nervous System ...

Benzgalantamine DR is under clinical development by AlphaCognition and currently in Phase I for Traumatic Brain Injury.